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Abstract 
Background: Closed-loop control algori thms in diabetes aim to calculate the op t imum insulin delivery to 
mainta in the patient in a normoglycemic state, taking the blood glucose level as the algori thm's main input. The 
major difficulties facing these algori thms w h e n applied subcutaneously are insulin absorpt ion t ime and delays in 
measurement of subcutaneous glucose wi th respect to the blood concentration. 
Methods: This article presents an inverse controller (IC) obtained b y inversion of an existing mathematical model 
and val idated wi th synthetic patients s imulated wi th a different model and is compared wi th a proport ional-
integral-derivative controller. 
Results: Simulated results are presented for a m e a n patient and for a popula t ion of six s imulated patients. The IC 
performance is analyzed for bo th full closed-loop and semiclosed-loop control. The IC is tested w h e n initialized 
wi th the heuristic opt imal gain, and it is compared wi th the performance w h e n the initial gain is deviated from 
the optimal one (±10%). 
Conclusions: The simulat ion results show the viability of using an IC for closed-loop diabetes control. The IC is 
able to achieve normoglycemia over long periods of t ime w h e n the optimal gain is used (63% for the full closed-
loop control, and it is increased to 96% for the semiclosed-loop control). 
Introduction 
IN THE LAST FEW DECADES a great research effort has been made in research in closed-loop diabetes control systems as 
a means of optimizing insulin therapy. Much work has been 
presented, but little of it has shown applicable results in 
subcutaneous use.1 Advances in algorithm development, the 
versatility of insulin pumps, and increased reliability of con-
tinuous subcutaneous glucose sensors are the foundation for 
the short-term development of an ambulatory closed-loop 
control system. 
The first electromechanical system meant to emulate pan-
creas function dates from 1974. Called Biostator, it was an 
experimental system for hospital use, using the intravenous 
route for measurement and intervention. The control algo-
rithm was a proportional-integral-derivative (PID) and glu-
cose feedback.2 
For practical ambulatory interaction the intravenous route is 
not viable. Continuous glucose measurement and insulin ad-
ministration require the subcutaneous route, which complicates 
control because of delays in both measurement and insulin 
action.3'4 To cope with delays it is necessary to use control 
topologies such as feed-forward or semiclosed-loop control.5'6 
Research in the artificial pancreas field had been revitalized 
by the growing availability of continuous glucose sensors, al-
though they still are not generally used in clinical practice 
because of their high cost, short life, and limited reliability.7 
Some of the closed-loop techniques applied in diabetes 
include PID approximations,8 model predictive control,9'10 
fuzzy control,11 and robust control.12 Semiclosed-loop control 
has been also evaluated as a means to reduce the peak post-
prandial glucose levels.13 All the previous approaches pro-
vide unilateral control in which the hormone insulin is used to 
lower the glucose values, but there is no other counter-
regulatory mechanism. In a recent experiment, the hormone 
glucagon has been used in a closed-loop control system to 
prevent hypoglycemic episodes in pigs.14 
This article presents an inverse controller (IC) for closed-
loop and semiclosed-loop diabetes control based on an in-
version model of the glucoregulatory system.15 
1Bioengineering and Telemedicine Group, Polytechnic University of Madrid; and 2Networking Research Centre for Bioengineering, 
Biomaterials and Nanomedicine, CIBER-BBN, Madrid, Spain. 
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Control by inversion is a technique that uses an inversion 
model to obtain infusion doses and also requires the avail-
ability of a glucoregulatory patient model. Various models 
have been proposed in the literature, from which we single 
out those of Bergman,16 Guyton et al.,17 Berger and Rod-
bard,18 Gómez et al.,19 Salzsieder et al.,20 Lehmann and 
Deutsch,21 Hovorka et al.,22 and Dalla Man et al.23 
Although a glucoregulatory inversion model has previ-
ously been used to obtain an estimation of plasma insulin,24 it 
has not been used in closed-loop control. The proposed IC has 
been tested in silico with a simulated patient population and a 
glucose sensor model. Although in silico performance of a 
control algorithm does not guarantee in vivo performance, it 
helps to test extreme situations and the stability of the algo-
rithm and to rule out inefficient scenarios.25 
can be positive or negative, Gkid is the renal excretion in hy-
perglycemic situations, and V is the dilution volume in the 
compartment. 
CH absorption,21 Gm, is calculated as: 
Gin(i) = uG(t)(e-rit -e-riyir2/(r2 - n) (2) 
where uG is the intake of CH (in g) and t\ and r2 are param-
eters defining CH type (Table 1). 
Peripheral consumption,17 Gout, is calculated as: 
Kx — (Gx + Km)/Gx 
Gout - iD(f) = XxGiv(í)cspíiv(í)/(Giv(f) + Km) 
Gmt-u(t) = KxGw(t)Gi/(Gw(t) + Km) 
Gout(i) = G0ut - ID(£) + G0ut - n(f) (3) 
Methods 
The glucoregulatory model 
The controller design is based on the glucose dynamic 
model of Guyton et al.17 and Lehmann and Deutsch,21 mod-
ified by Gómez et al.,19 and on the insulin dynamic described 
by Berger and Rodbard18 adapted to the lispro type insulin.26 
The glucose model21 is a compartmental model whose 
parameters may be consulted in Table 1. The glucose balance 
equation is: 
where Gout_ID is the insulin-dependent glucose uptake, Gout_n 
is the non-insulin-dependent glucose uptake, Km is the 
Michaelis-Menten constant, Gx is the reference glucose level, 
c is the consumption ratio for insulinemia, Iw is the plasma 
insulin concentration in equilibrium, sp is the peripheral in-
sulin sensitivity, and Gi is the insulin-independent glucose 
consumption. 
Hepatic balance G N H GB (glycogenesis and glycolysis) is 
modeled with the following equations obtained from experi-
mental data17: 
dGwWdt = (Gin(f) - Gout(f) + GNHGB(f) - Gkid(f))/ V (1) 
where Gw is the concentration of glucose in the blood, G^ is 
the glucose flow into the compartment due to the intestinal 
absorption of ingested carbohydrates (CHs), Gout is the pe-
ripheral consumption, G N H GB is the hepatic balance, which 
gl(t)--
#(*)= 
#(*)= 
= cu-cu-G$(t)/(d*+G$(t)) 
--C2i-c22-Gc^{t)/{cfi+G^{t)) 
--c31+c32-G%(t)-e-^G^ 
+ c35-G$(t)-e-c^G^ 
GNHGB(Í) =gi(t) +g2(t) • e-?3«iiv(fK/4 (4) 
TABLE 1. IC PARAMETERS 
lb 
Ke 
Ki 
K2 
a 
b 
s 
T50 
Gx 
Km 
RTG 
GFR 
Gi 
V 
W 
r-, 
r2 
C 
sP 
sh 
Definition 
Basal insulin 
lst-order constant for insulin elimination 
lst-order production active insulin 
lst-order removal active insulin 
Insulin-specific parameter (lispro) 
Insulin-specific parameter (lispro) 
Insulin-specific parameter (lispro) 
Time for the half absorption of an insulin dose 
Glycemic reference level 
Michaelis-Menten constant 
Threshold for kidney glucose elimination 
Kidney glomerular filtration rate 
Glucose consumption independent from insulin 
Dilution volume in the compartment 
Body weight 
CH absorption parameter 
Fast absorption 
Low absorption 
CH absorption parameter 
Fast absorption 
Low absorption 
Peripheral glucose consumption dependent on the insulin concentration 
Peripheral insulin sensitivity 
Hepatic insulin sensitivity 
Value Units 
11 
5.4 
0.025 
1.25 
0.02 
1 
1.7 
95 
180 
160 
1 
1.62 
120 
70 
0.08 
0.017 
0.09 
0.0173 
0.045 
0.5 
0.6 
mU/L 
H - 1 
h - 1 
h - 1 
h/U 
H 
h/U 
H 
mg/dL 
mg/dL 
mg/dL 
dL/min 
mg/min/kg 
dL 
kg 
min - 1 
min - 1 
min - 1 
min - 1 
mg L/min/kg/mU 
where g\ is the balance hepatic first component, g2 is the linear 
hepatic coefficient, g3 is the exponential hepatic coefficient 
(mmol/h), c¡j are adjustment parameters, and sh is the hepatic 
insulin sensitivity. 
Renal excretion (glycosuria),17 Gkid, is calculated as: 
r ... (GFR(GMt)-RTG)/MG GN>RTG ... 
G k i d ( í ) = \ 0 Glv<RTG ( 5 ) 
where GFR is the glomerular filtration rate and RTG is the 
renal threshold for glucose. 
The insulin model18 is composed of two compartments, 
which respectively model active insulin and insulin in equi-
librium starting with the absorption of external insulin ad-
ministered subcutaneously: 
íabs(í) = «i(í)-sís7lo/(í(7|, + í sr) (6) 
where Iabs is the insulin absorbed, ut is the insulin dosage, s is 
a specific parameter for each insulin type, and T50 is the ab-
sorption time of 50% of an insulin bolus: 
dl(t)/dt = labs(t)/V-kel(t) 
dl,(t)/dt = hl(t)-k2l,(t) 
(7) 
(8) 
where Ia and I are active and plasma insulin, respectively, kx 
and k2 are insulin production constants, and ke is an elimi-
nation constant. 
When the blood insulin concentration is in equilibrium, íw 
is calculated as: 
Íw(t) = (k2/h)J2la,n(t-tn) (9) 
where N is the number of previously administered micro-
boluses that still show activity at instant t, ia/„ is the insulin 
due to the bolus n, and tn is the administration time of bolus n. 
The sensor model 
The continuous glucose sensor was simulated with the 
intravenous-subcutaneous glucose dynamics defined by 
Facchinetti et al.27 (see Eq. 10): 
dGsc(t)/dt = - (g/r)Gsc(t) + (1 A)Giv(i) (10) 
where Gsc is the subcutaneous glucose, g and % are parameters 
related to the transfer rate coefficients, and Gw is the blood 
glucose. 
Closed-loop control methodology 
Figure 1 shows the topology of the IC in a full closed-loop 
IC (FCL-IC) configuration, which is composed of an inversor, 
a CH intake estimator, and an insulin dose calculator. The IC 
is a dual feedback controller. The main feedback is the con-
trolled variable, the glucose continuous glucose monitoring 
(CGM), and the second feedback is the variable insulinemia. 
The inversor. The inversor calculates the insulin in ideal 
equilibrium (IWo) that is required to neutralize CH intake 
disturbances. The inversor may be considered as an intrave-
nous control strategy. The regulator has two inputs: the glu-
cose measurement, G sc , and an estimation of meal absorption, 
G¡n. The regulator output is Iwo-15 
The inversor is formulated through differential Eq. 1 under 
non-glycosuria conditions (Gkid = 0). The equation is dis-
cretized using a rectangular rule where T is the sample period: 
Gsc(fcT) - Gsc((fc - 1)T) = T(Gin(kT) - G0Ut(kT) + GNHGB(kT))/V 
(11) 
The algorithm considers that in persons with type 1 dia-
betes, the ingested CHs (Gin) are distributed as glucose used 
by the tissues (Gout) a n d glucose stored in the liver (G N H GB) in 
a proportion of 50% each.28 
The optimal insulinemia the patient should have in order to 
absorb the intake uG is obtained through the inversion of Eqs. 
3 and 4: 
ÍGout-ID^HO.SGinW 
1 GNHGBW = - 0.5Gi„(fc) + Gout _ n(fc) (12) 
iivP(fc, Gsc) = 0.5Gin(fc) • (Gsc(fc) + Xm)/XxGsc(fc)c • sp 
iivhfo Gsc) = - (h/g3(k)sh) ln( - 0.5Gin(ic) 
+ KxGSc(k)Gi/(Gsc(k)+Km)-g1(k))/g2(k) (13) 
hv(k, Gsc) = iivp(fc, Gsc) + íivhfo Gsc) (14) 
where iiVp and l^vh are the concentrations of insulin required 
in the peripheral consumption and hepatic balance for correct 
intake absorption, respectively. 
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FIG. 1. Closed-loop subcutaneous IC and patient model. Gtarget, glucose target; TIV, insulinemia estimation; G sc , subcuta-
neous glucose measurement; uG, CH intake; G¡n, CH absorption estimation; IWo, optimum insulinemia; and uh insulin 
delivery. 
The target insulinemia is calculated with Eq. 13 to reach the 
glucose target: 
harget(k, Gtarget) — hv^(k, Gtarget) + IiVh(k, Gtarget) (15) 
The required insulin has to take into account the insulin 
that is already active in plasma from previous administration. 
Equations 14 and 15 calculate the incremental plasma insulin 
concentration: 
Aíiv(fc)=íiv(fc)-íiv(^ 
A/target^) = W e t W - Iwify 
(16) 
where Target is the insulinemia required to reach the glucose 
target, Iw is the insulinemia to absorb the intake, and íw is the 
equilibrium plasma insulin due to previous administrations. 
The optimum insulinemia to achieve the target and to 
absorb the intake (irvo) is the sum of the two incremental 
terms in: 
hvo(k) = itargetW + ¿IV W - 2IMQ (17) 
The intake estimator. In an automatic regulator using glu-
cose measurement as its only input, insulin starts to be admin-
istered once the effects of the intake appears in the glycemic 
levels, which means some minutes after the meal. 
The proposed controller includes a CH absorption intake 
estimator that permits detection, at an early stage, of rising 
glucose and thus reduces as much as possible the time lapse 
between the meal and the start of insulin administration by 
the algorithm. 
The intake estimator estimates the absorption of CHs by 
way of a new formulation of Eqs. 1-4: 
Goutifc) = KxGsc(k)(cspiw(k) + Gi)/(Gsc(fc) + Km) 
GNHGBW =&(*, Gsc) +&(*, Gsc)e-g3(k'G^IMk)Sh/h 
Gin(fc) = V(Gsc(k) - Gsc(k - 1))/T + Gmt(k) - GNHGBW 
(18) 
where Gout and G N H G B are estimations of the patient's pe-
ripheral consumption and hepatic balance, respectively, Gsc 
is the subcutaneous glucose, TIV is the insulinemia estimation, 
gi is the estimation of the hepatic coefficients, and G¡n is the 
estimation of CH absorption. 
Dose calculator. Given that the inversor output is the 
plasma insulin concentration, the controller requires a method 
to calculate the insulin doses in order to obtain the optimal 
insulinemia in the least time possible, considering previously 
administered insulin and absorption delay. The dose calcu-
lator computes the required subcutaneous insulin pump in-
fusions following the inversion concept and is based on the 
inversion of Eqs. 6-9: 
u(k) =KUJ2 <?;[Avo(f)/df'']f=icT 
q0 = VKe/f 
qi=V(l+Ke/K2)/f 
q2 = V/(fK2) 
f=s(kTyr50/(kT(r50 + (kT)sf) 
(19) 
where u is the infusion dose, Ku is a gain adjusted to the 
patient, c¡¡ are the terms resulting from the inversion, and IWo 
is the optimal insulinemia;/is a common term. The rest of the 
parameters are from Eqs. 1, 7, and 8. 
Insulin dose constraints. To guarantee patient safety 
some constraints are applied to the calculated insulin doses: 
• Null insulin microinfusions are not permitted except 
in the case of the onset of a hypoglycemic episode 
(Gsc < G0ff), when insulin administration is suspended 
until glycemia reaches a safety threshold (GSc > Gon). 
When the pump is suspended, a minimum pump dose 
(lip) is administered every 60min to avoid catheter oc-
clusions. 
• In the normoglycemic state, a minimum basal dose (ub) 
is administered whenever the controller proposal falls 
below (ub). 
• To prevent postprandial hypoglycemic episodes, insulin 
infusion is limited to a maximum value calculated as 
follow: over the preceding 2 h, it will not exceed 30% of 
the total amount of daily insulin recommended for each 
patient. 
Equation 20 shows the insulin dose constraints: 
u\ — < 0 or u 
Gsc > Goff if MI = u 
Gsc > Gon if u\ — Mb 
Í Gsc<Goff if ui = u 
P \ G S C < G o n if Mi=Mb 
Mb u(k)<u\, 
Mm u(k)>um 
(20) 
where ut is the controller-computed insulin dose, Gsc is the 
subcutaneous glucose, Mp is the smallest pump bolus, Goff is 
the hypoglycemic safety threshold, Gon is the activation 
threshold, ub is the basal bolus, and Mm is the maximal bolus. 
Semiclosed-loop control methodologies 
The use of a semiclosed-loop IC (SCL-IC) approach could 
minimize the harmful effects of the delays. In a semiclosed-
loop scenario the patient should provide to the algorithm 
information about the meals both in time and in CH content. 
The insulin bolus can be calculated with a personalized CH to 
insulin ratio. In this work, a percentage of the insulin bolus 
is administered prior to the meal, so the insulinemia starts 
to increase before the rise in the subcutaneous glucose 
measurement. 
Simulation studies 
The objective is to analyze in silico the impact of the FCL-IC 
on glucose control and the further improvement that can be 
obtained with an SCL-IC. 
The patient population was simulated using the compart-
mental model defined by Hovorka et al.22 and the six patients 
(numbers 1-6) identified by use of a dual-tracer dilution 
methodology. For single patient studies, we used the mean 
patient for the same population (patient number 0).22 
The same meal plan is established for all the simulated 
patients: 205g/day CH divided into five intakes (45 g at 
breakfast, 7 a.m.; 70 g at lunch, noon; 5 g at snack, 4 p.m.; 80 g 
at dinner, 6 p.m.; and 5 g at snack, 11 p.m.).23 
The IC is applied to the simulated population using 
the following common parameters: Target —100 mg/dL; 
Goff = 100 mg/dL; Gon = 105 mg/dL; ub = 0.05 IU; wp = 0.05 IU; 
wmax = 5 IU; g = 0.92; % = 19.52 min. 
The initial gain value (Ku) was heuristically adjusted 
for each patient and for each control mode (FCL-IC or SCL-
IC) to obtain an optimal glucose profile in the range of 
70-180 mg/dL while trying to avoid hypoglycemic events 
when using the controller. The SCL-IC administers 50% of the 
insulin bolus 15 min in advance of the announced meal. 
The performance of the IC is analyzed when running with 
the heuristic optimal gain and is compared with the perfor-
mance when the initial gain is deviated from the heuristic one 
(±10%). 
FCL-IC insulin delivery is compared with the insulin de-
livered by a PID controller similar to that defined by Steil et al.8 
(it has been initialized with Kp — 0.001, Ti = 450min, and 
Tá — 66 min), but applying, in addition, the insulin dose con-
straints defined in this work (pump suspension when 
Gsc < G0ff, minimum pump dose, etc.). In both cases, the 
sample measurement period and insulin infusion period are 
5 min long. 
In the previous simulations, the sensor model27 considered 
the plasma interstitial lag, but not the presence of noise in the 
measurement. To assume a white noise across the whole 
spectrum is generally inaccurate.29 Therefore, in order to un-
derstand the impact of real noise on the IC, a CGM profile is 
used as input to the controller. The CGM data are from a 
patient wearing the Guardian® RT CGM System (Medtronic-
Minimed, Northridge, CA) for 3 days. The input to the con-
troller is the sensor data without any filtering process. We 
point out that, in this case, insulin therapy was open loop, so 
the glucose profile was retrospectively used as IC input, but 
the IC output (insulin administration) was not applied to the 
patient. 
Results 
Figure 2 shows a 2-day simulation for the FCL-IC and SCL-
IC when applied to simulated Patient number 0 (the mean 
patient22). The upper graphs display the insulin infusion, and 
the lower graphs display the subcutaneous glucose concen-
tration. The FCL-IC has been initialized with Ku — 3.3xl0~3. 
The SCL-IC has been initialized with Ku — 2 Ax 10~3, and the 
prandial insulin bolus is administered 15 min before the meal. 
Table 2 summarizes the results presented in Figure 2: average 
daily insulin; the maximum, minimum, and mean glucose 
values; the number of glucose samples above and below the 
target range (70-180 mg/dL); and the area under the curve 
(AUC) above 180 mg/dL. 
Figure 3 shows a 2-day simulation for the FCL-IC and SCL-
IC when applied to the simulated population (without patient 
number 0). The graphs display the average glucose profile and 
the dispersion (mean ± SD) for the optimal gain (Ku), an over-
dimensioned gain (Xu+10%), and an under-dimensioned 
gain (Ku —10%). Table 3 summarizes the results presented in 
Figure 3: maximum, minimum, and mean glucose values; 
the number of samples above and below the target range (70-
180 mg/dL); and the AUC above 180 mg/dL. 
Figure 4 shows the comparison between FCL-IC insulin 
delivery and PID insulin delivery in a 2-day simulation for 
simulated patient number 0 (the mean patient). The upper 
20 25 30 
Tims (hours) 
ku+10% 
300 
250 
200 
150 
E 100 
50 
0 1 A '• A -^A A- 1 A 1 UA L-A A- v*. 1 A-
10 15 20 25 30 
Time (hours) 
35 
ku-10% 
300 
250 
200 
Í 150 
100 -
50 
0 
10 15 20 25 30 
Time fhoursl 
35 40 
40 45 
* 4 ' 4 J-A A * A ' — * *-* * A 1 *-
45 
300 
250 
200 
,150 
100 
50 
0 
20 25 30 
Time (hours) 
20 25 30 
Time (hours) 
ID 15 20 25 30 
Time fhoursi 
35 
¿ A ' tr 
40 45 
FIG. 3. Impact of the controller gain initialization (Ku) on the subcutaneous glucose concentration in the population of 2 days of simulation in response to (left) the FCL-IC 
and (right) the SCL-IC: (a) Ku — heuristically adjusted gain, (b) over-dimensional gain, and (c) under-dimensional gain. The triangles indicate the presence of a meal. Color 
images available online at www.liebertonline.com/dia. 
TABLE 2. RESULTS OF THE FCL-IC AND SCL-IC SIMULATIONS FOR PATIENT NUMBER 0 
Gain, control mode 
Ku+W% 
FCL-IC 
SCL-IC 
Ku 
FCL-IC 
SCL-IC 
Ku -10% 
FCL-IC 
SCL-IC 
Daily 
insulin (III) 
39 
41 
37 
40 
36 
38 
Glucose max/min 
(mg/dL) 
304/56 
223/62 
303/71 
229/71 
303/83 
230/85 
Glucose (mean ± SD) 
(mg/dL) 
136 ±66 
115 ±39 
148 ±64 
124 ±39 
154 ±58 
136 ±38 
% samples 
<70/>180 mg/dL 
14/27 
7/6 
0/30 
0/11 
0/83 
0/16 
AUC > 180 
(mg/dL/min) 
68 
8 
80 
12 
78 
19 
graph displays FCL-IC insulin infusion, the middle graph 
displays PID insulin infusion, and the lower graph displays 
the subcutaneous glucose concentration. The numerical re-
sults with FCL-IC are presented in Table 2. The numerical 
results with PID are: daily insulin — 36.1 IU; Gmax = 317.5 
mg/dL; Gmin = 65.8mg/dL; Gmean±SD = 161.4±70.2mg/dL; 
percentage of glucose samples below 70 mg/dL — 2.5%; per-
centage of glucose samples below 180 mg/dL — 36%; and 
AUC above 180 mg/dL = 69. 
Figure 5 shows the SCL-IC response when a real CGM 
profile is used as input to the controller. The CGM data are 
from a patient wearing the Guardian RT CGM System. The 
upper graph shows the proposed subcutaneous insulin infu-
sion, and the lower graph shows the subcutaneous glucose 
concentration. We point out that this simulation can help to 
understand the impact of noise on IC behavior, but, in this 
case, the real glucose profile is retrospectively used as IC input 
and the insulin was not delivered to the patient. 
Conclusions 
This work has shown the viability of utilizing an IC for 
closed-loop diabetes control in simulation studies. The IC is 
able to achieve normoglycemia over long periods of time 
when the optimal gain is used (63% for the FCL-IC but in-
creased to 96% for the SCL-IC). 
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FIG. 4. Two days of simulation of the response of patient number 0 to the FCL-IC and the PID: (upper graph) FCL-IC 
insulin infusion, (middle graph) PID insulin infusion, and (lower graph) subcutaneous glucose infusion (solid line, FCL-IC; 
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TABLE 3. RESULTS OF THE FCL-IC AND SCL-IC 
SIMULATIONS FOR THE SIX-PATIENT POPULATION 
Gain, 
control 
mode 
Ku+W% 
FCL-IC 
SCL-IC 
Ku 
FCL-IC 
SCL-IC 
Ku -10% 
FCL-IC 
SCL-IC 
Glucose 
max/min 
(mg/dL) 
266/58 
195/55 
288/70 
229/71 
306/73 
239/72 
Glucose 
(mean ± SD) 
(mg/dL) 
125 ± 3 7 
101 ± 28 
147 ± 4 7 
108 ±28 
160 ±52 
122 ±39 
% samples 
<70/>180 
mg/dL 
6/10 
5/1 
0/37 
0/4 
0/43 
0/10 
AUC> 
180 mg/ 
dL/min 
11 
<1 
59 
3 
78 
15 
The proposed IC responds to a meal with a nonsymmetrical 
distribution of the insulin administered, with higher rates just 
after the intake than some minutes later. This nonlinear be-
havior helps to reduce the incidence of postprandial hyper-
glycemic episodes and cannot be observed in linear 
controllers such as the PID (see Fig. 4). 
However, as observed by other authors, automated closed-
loop controllers cannot achieve the glucose target after meals. 
Those postprandial hyperglycemic episodes cannot be avoi-
ded because of the delays introduced by subcutaneous mea-
surement and subcutaneous insulin absorption. The results 
obtained with the simulated patient group show that the FCL-
IC is able to achieve normoglycemia over long periods of 
time when the optimal heuristic Ku gain is used, but the per-
formance of the algorithm decreases when the gain is not 
the optimal one. Table 3 shows that an over-dimensioned 
gain provokes hypoglycemic episodes (6%) and an under-
dimensioned gain causes longer and more marked hyper-
glycemic episodes (43%), with an AUC of 78 mg/dL/min. 
As expected, the semiclosed-loop approach is an im-
provement over full closed-loop glucose control as it is able to 
maintain normoglycemia over longer periods of time (96% vs. 
63%). In additional, it is observed that the SCL-IC is more 
independent of a nonoptimal estimation of real subjects' pa-
rameters (controller gain): for all the gains considered, SCL-
IC-related hypoglycemic events are similar to those observed 
with the FCL-IC, but the hyperglycemic episodes are reduced 
(Table 3). The reason is that a significant percentage of the 
insulin is administered manually before the meals and follows 
the patients' conventional daily therapy. The inconvenience of 
the SCL-IC is that it would require the patient to enter the 
mealtime and CH content into the controller. Thus, we lose 
the concept of an automated system, but it minimizes the 
effects of the delays. 
The results show that both IC versions are protected against 
excessive insulin administration (over-dimensioned gains). 
This behavior is due to the insulin constraints that we have 
defined to avoid hypoglycemic events. It should be pointed 
out that the constraints are external to the controller and could 
be used in combination with any other control methods. 
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presence of a meal. Color images available online at www.liebertonline.com/dia. 
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As a first approach, the SCL-IC presented here adminis­
ters 50% of the bolus before the meal and takes into ac­
count a fixed ratio of CH to insulin throughout the day. More 
in-depth studies should be carried out to assess the best 
approach. 
The findings presented in Figure 4 suggest that the 
presence of noise in the glucose profile will degrade IC per­
formance, resulting in a spurious insulin profile. A more in-
depth analysis is required to characterize CGM sensor noise 
in order to simulate the impact on the IC. 
Some keys that could improve any full closed-loop control 
are the development of adaptation mechanisms, the use of 
glucose prediction, the definition of different glucose targets 
over time, and the definition of initialization procedures. The 
use of prediction methods will bring the performance of the 
full closed-loop closer to that of the semiclosed-loop. 
In future works, we will also explore the inversion of other 
metabolic models to design new inverse control algorithms, 
but the inversion of compartmental models is a complex task 
in which the complexity is inversely proportional to the model 
nonlinearity. 
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